KLF6 (Krueppel-like factor 6), is also known as BCD1, COPEB, CPBP and ST12. KLF6 contains zinc-finger domains and is thought to be a transcriptional activator binding to GC box motifs. KLF6 is involved in B-cell growth and development and has been shown to be highly expressed in placental cells as well as other tissues including the spleen, thymus, prostate, testis, small intestine and colon. KLF6 defects have been linked to gastric cancer (GASC) and prostate cancer (PC).

~37 kDa observed. The calculated molecular weight is 32 kDa, however KLF6 has been shown at ~37 through ~40 kDa bands in western blots (Kimmeleman, A. C., et al. (2004). Oncogene. 23:5077-5083).

GST-tagged recombinant protein corresponding to human KLF6.

Research Category
Neuroscience

Research Sub Category
Developmental Signaling

This KLF6 antibody is validated for use in WB & IHC for the detection of the KLF6 protein.

Western Blotting Analysis: 0.5 µg/mL from a representative lot detected KLF6 in 10 µg of human placenta tissue lysate.
Immunohistochemistry Analysis: A 1:200 dilution from a representative lot detected KLF6 in human placenta tissue.

Format: Purified

Protein G Purified

Purified mouse monoclonal IgG2bκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.

Control
NIH-3T3 cell lysate

Evaluated by Western Blotting in NIH-3T3 cell lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected KLF6 in 10 µg of NIH-3T3 cell lysate.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.